Instylla’s Resorbable Embolic Technology Gets FDA Nod for Hypervascular Tumors
Instylla, Inc., a privately held innovator in resorbable embolic technologies for peripheral vascular embolization, has announced that the U.S. Food and Drug Administration (FDA) has granted premarket approval (PMA) for its flagship product, the Embrace™ Hydrogel Embolic System (HES). The…